Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eluxadoline dose-ranging study in adolescents with IBS-D
2017-003770-14Phase 2Unknown
- Sponsor
- Allergan
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing Eluxadoline dose arm(s) with Placebo (2 arms). Primary endpoint: Change from baseline in 24-hour stool consistency. Status: unknown.
02
Drugs
eluxadoline
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2017-003770-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003770-14.